Advanced Enzyme Technologies Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Advanced Enzyme Technologies Ltd trades at ₹321, in a confirmed uptrend and 9 weeks into that stage. That is −1.7% against its own 200-day average. It sits at 49% of a 52-week range of ₹266 to ₹377. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (4 weeks and counting).

Today the stock is in a confirmed uptrend — week 9 of stage 2, confirmed. At ₹321 it trades −1.7% versus its 200-day average and sits at 49% of its 52-week range (₹266–₹377).

Against the market, two honest reads. Cumulative: over the last 9.9 years the stock moved +13% while the NIFTY 500 moved +221% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-06-25) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 25th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Advanced Enzyme Technologies Ltd trades at 22.9× P/E, near the bottom of its own range — cheaper only 25% of the time. Its long-run median P/E is 27.7×, measured across 10.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 22.9× is near the bottom of its own range — cheaper only 25% of the time, against a long-run median of 27.7× measured over 10.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +28.6% against a −1.2% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the −5.0%/yr price move, ~+1.2%/yr came from earnings growth and ~−6.2 pp from the multiple (compressing); over 10y, of the +1.2%/yr price move, ~+5.4%/yr came from earnings growth and ~−4.2 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.0% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Advanced Enzyme Technologies Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −7.1% at the trough to +66.7%, a 2-quarter improving streak (single-quarter readings), ROCE holding at 14.0%. The read is built from 10 quarters across 3 curves, on partial evidence.

Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

71.2/100 — rank 1 of 3 in Seeds/Tissue Culture/Bio Technology · 76% evidence confidence

Advanced Enzyme Technologies Ltd scores 71.2 out of 100 against the 3 companies it is compared with in Seeds/Tissue Culture/Bio Technology, ranking 1. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.

The four contributions add to the total exactly: 27.8 + 17.5 + 12.1 + 13.8 = 71.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Advanced Enzyme Technologies Ltd reported ₹203 Cr of revenue in the Mar 26 quarter, +21.6% year on year. That is the 6th straight quarter of year-on-year growth. Over 10 years it has compounded at 9.8% a year. The last full year, FY26, came in at ₹746 Cr. The last four reported quarters add to ₹746 Cr.

Advanced Enzyme Technologies Ltd reported ₹203 Cr of revenue in the Mar 26 quarter, +21.6% year on year. That is the 6th straight quarter of year-on-year growth. Over 10 years it has compounded at 9.8% a year. The last full year, FY26, came in at ₹746 Cr. The last four reported quarters add to ₹746 Cr.

FY26 revenue came in at ₹746 Cr (+17.1% on the year), capping 10 years at 9.8% compound. The latest quarter (Mar 26) printed ₹203 Cr, +21.6% year on year — the 6th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +17.5% growth against the decade's 9.8% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +17.1% over the last 4 quarters against +9.3%/yr over the last 8 — accelerating; TTM profit +29.1% vs +12.8%/yr — accelerating.

→ Revenue grew — did margins hold as it scaled? Next: 31.0% this quarter (+4.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Advanced Enzyme Technologies Ltd's operating margin is 31.0% in the Mar 26 quarter, +4.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 21.0% to 47.0%. The current quarter sits inside that band.

Advanced Enzyme Technologies Ltd's operating margin is 31.0% in the Mar 26 quarter, +4.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 21.0% to 47.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 31.0%, +4.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 21.0%–47.0%.

Why the margin moved: operating margin went +3.8 pp year on year while gross margin went −0.4 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

→ Margins held — did that reach the bottom line? Next: profit +66.7% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Advanced Enzyme Technologies Ltd earned ₹45.0 Cr of net profit in the Mar 26 quarter, +66.7% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹174 Cr. The 10-year compound rate is 8.5%. That is 22.2% of the quarter's revenue. The same quarter a year earlier earned ₹27.0 Cr.

Advanced Enzyme Technologies Ltd earned ₹45.0 Cr of net profit in the Mar 26 quarter, +66.7% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹174 Cr. The 10-year compound rate is 8.5%. That is 22.2% of the quarter's revenue. The same quarter a year earlier earned ₹27.0 Cr.

Mar 26 profit was ₹45.0 Cr, +66.7% year on year — the 4th consecutive quarter of growth. On the full year, FY26 printed ₹174 Cr (+29.9%), and the 10-year compound rate is 8.5%.

Why profit moved: revenue contributed +21.6% and the margin +4.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +31.9% vs revenue +17.5%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

→ Profit rose — but did the cash follow? Next: 99% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 99% of Advanced Enzyme Technologies Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹157 Cr of operating cash against ₹174 Cr of profit. After ₹82.0 Cr of capital spending, ₹75.0 Cr was left as free cash.

FY26: operating cash of ₹157 Cr against reported profit of ₹174 Cr, leaving free cash of ₹75.0 Cr after ₹82.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 99% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 99%: the cash cycle tightened 22 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 1.6× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹184 Cr of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Advanced Enzyme Technologies Ltd's cash conversion cycle runs 331 days in FY26, down from 353 days in FY21. Capital spending ran ₹184 Cr over the last 3 years. At FY26 sales of ₹746 Cr each day of that cycle holds about ₹2.0 Cr, so roughly ₹677 Cr sits inside the business at any moment.

FY26: debtors at 71 days, inventory at 335 days — roughly 11.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 331 days, tighter than FY21's 353.

The full loop: cash goes out to suppliers and production on day 0; stock waits 335 days to sell; customers pay about 71 days after that; and suppliers themselves are paid at 76 days — netting out to the 331-day cycle.

In money terms: at FY26 sales of ₹746 Cr, each day of the cycle holds about ₹2.0 Cr — so the 331-day loop keeps roughly ₹677 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹184 Cr over the last 3 fiscal years against ₹112 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹51.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 14%.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Advanced Enzyme Technologies Ltd earns a ROCE of 14% in FY26. That is up from a trough of 12% in FY14. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 23.3% net margin on 0.41× asset turns.

FY26 ROCE is 14%, recovered from a FY14 trough of 12% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 23.3% net margin × 0.41× asset turns × 1.12× balance-sheet leverage ≈ 10.7% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.0% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.02.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Advanced Enzyme Technologies Ltd carries ₹32.0 Cr of borrowings against ₹1,632 Cr of equity in FY26, a debt-to-equity of 0.02. Operating profit covers the interest bill 58×. Over 5 years borrowings went from ₹23.0 Cr to ₹32.0 Cr. Capital spending ran ₹184 Cr across the last 3 of those years.

FY26: borrowings of ₹32.0 Cr against equity of ₹1,632 Cr — a debt-to-equity of 0.02. Operating profit covers the interest bill 58×. Over 5 years borrowings went from ₹23.0 Cr to ₹32.0 Cr while capital spending ran ₹184 Cr in just the last 3 — part of the build-out is riding on borrowed money.

The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.0% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

→ Who owns this, and are they adding or leaving? Next: Foreign institutions added 14.7 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions added 14.7 points of Advanced Enzyme Technologies Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 26.7% of the company. Domestic institutions moved −3.3 points over the same window, to 4.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: +14.7 points over 8 quarters to 26.7%; Domestic institutions: −3.3 points over 8 quarters to 4.8%; Promoters: +0.2 points over 8 quarters to 43.3%.

Why the register moved: rotation — foreign institutions +14.7 points against domestic institutions −3.3 points over 8 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Advanced Enzyme Technologies Ltd: the Z-score is withheld — it comes from the second data source this page could not reconcile, and a solvency score is not worth printing on a number two sources dispute. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

The safety line in one sentence: the Z-score is withheld — it comes from the second data source this page could not reconcile, and a solvency score is not worth printing on a number two sources dispute.

Frequently asked questions